CBLL · Ceribell, Inc.
$23.33
+0.08 (+0.34%)
At close · Aug 14
Market Cap
$895.36M
Shares
38.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.33
Open$23.25
Day$23.03–23.55
52W close$10.92–23.43
Avg vol 30d399K
Short int2.0M · 5.3% float · 5.5d
Short vol44%
Last earningsAug 10, 2026
DataOct 2024–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 9, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+24%
above
Price vs 50-day avg
+23%
above
RSI (14)
78
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+17%
trailing
YTD return
+6%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $19 › 200d $19 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +17 funds added
Insider flow
Distributing
Net -$4.7M over 90 days · 100% sells
Short interest
Rising
5.26% of float · ▲ +9.2% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
122 holders — near 1-yr high, broad support
Squeeze score
98
high risk · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
88%
expanding
EPS growth
+57%
Y/Y
Free cash flow
$-41.6M
Balance sheet
$20.7M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
Revenue
· full year 2026
$114M – $117M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
Revenue
· full-year 2025
$87M – $89M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+24%
Bullish
Price vs 50-day avg
+23%
Bullish
RSI (14)
78
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Golden cross
50d $19 › 200d $19 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +17 funds added
Insider flow
Distributing
Net -$4.7M over 90 days · 100% sells
Short interest
Rising
5.26% of float · ▲ +9.2% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
122 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $23 · 99%
Range high $23
vs 200-day avg +24%
vs 50-day avg +23%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -$9.82M | the three months ended June 30, 2026 filing | — |
| Adjusted EBITDA loss non-GAAP | $9.8M | Q2 2026 | — |
|
|
|||
| EBITDA (Non-GAAP) non-GAAP | -$19.74M | the three months ended June 30, 2026 filing | — |
| Gross margin | 92% | Q2 2026 | — |
|
|
|||
| Total active accounts | 712 | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBLL
this stock
Ceribell, Inc.
|
$895.36M | +6.4% | +36.1% | — | 5.3% |
|
ABT
Abbott Laboratories
|
$194.07B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$133.18B | -3.5% | +11.2% | 36.0 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBLL | +24.0% | +24.6% | +16.7% | +31.9% | +6.4% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +23.6% | +20.2% | +2.9% | +28.0% | -7.5% |
Key facts
CIK
1861107
CUSIP
15678C102
13F (30d)
122 filings
117 filers
Visit website
Investor relations